AI-Tomo registration accuracy, simulated cases
3.15 mm mean error
- EndpointRegistration accuracy
- Population500 simulated cases based on human CT scans
- Tested versionLungVision System configuration described in K240943
FDA-cleared profile
BodyVision Medical Ltd. · Radiological images; modality varies or is not specified in FDA list · FDA-cleared (510(k))
Authorized purpose: The LungVision System enables users to segment previously acquired 3D CT datasets and overlay and register those segmented datasets with fluoroscopic live X-ray images of the same anatomy to support catheter or device navigation during pulmonary procedures.
Overview status: Source-reviewed overview
Workflow role has not yet been reviewed for this navigation pilot.
A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources
Clinical takeaway. Clinical role: The LungVision System enables users to segment previously acquired 3D CT datasets and overlay and register those segmented datasets with fluoroscopic live X-ray images of the same anatomy to support catheter or device navigation during pulmonary procedures.
Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports bench testing, including requirements verification, hazard mitigation and system performance testing, plus testing on physical and simulated lung models. Mean accuracy was 3.15 mm with 3.2 mm std for 500 simulated cases measuring registration error only, and 5.34 mm with 3.32 mm std for 191 cases based on real CT and CBCT scans. Physicians validated AI-Tomo on historical LungVision cases; lesion marking accuracy was comparable using CABT and AI Tomo images. Results are as reported in the FDA submission, not independent validation.
Evidence context not reviewed for this FDA record.
Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.
Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.
Packet wording: "Testing includes verification testing of the requirements, testing of hazards mitigations and performance testing of the system. Testing has also been performed on physical and simulated lung models representing deformable tissue." … "This method uses simulated data in a simulated environment, and therefore measures the registration error only, without additional real-world inaccuracies: CT to body divergence, jig estimation errors, fluoroscope distortion etc. The mean accuracy calculated for 500 cases is 3.15 mm with 3.2 mm std.". Read from the exact FDA decision document on 2026-11-14.
Evidence
Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.
Packet wording: "Testing includes verification testing of the requirements, testing of hazards mitigations and performance testing of the system. Testing has also been performed on physical and simulated lung models representing deformable tissue." … "This method uses simulated data in a simulated environment, and therefore measures the registration error only, without additional real-world inaccuracies: CT to body divergence, jig estimation errors, fluoroscope distortion etc. The mean accuracy calculated for 500 cases is 3.15 mm with 3.2 mm std.". Read from the exact FDA decision document on 2026-11-14.
Sensitivity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, study design, and source if separately verified.
Specificity is not promoted as a product-wide endpoint. Compare only an exact endpoint, threshold, population, version, study design, and source if separately verified.
3.15 mm mean error
3.64 mm mean error
5.34 mm mean error
K240943
The FDA summary describes simulated, rigid-model, and CBCT registration testing; the reported means are not a product-wide clinical-outcome or navigation-success claim.
Safety and lifecycle
Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.
Exact-identifier review does not prove absence of all product-family safety signals.
Price not public here; enter your quote
Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.
No separate named-product payment identified in reviewed public material
Centers for Medicare & Medicaid Services · United StatesThis is not a product-specific reimbursement determination. Build a local total-cost and value model and verify payer, site-of-service, coding, and coverage assumptions independently.
Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.
No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.
Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.
Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner
No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.
Source context, not route validation: Previously acquired 3D CT datasets and live fluoroscopic X-ray images of the same anatomy.
Scope: Exact FDA submission.
Confirm scanner/model, protocol, series completeness and both software builds.
Field checked 2026-09-04 · FDA 510(k) K240943: LungVision
Source context, not route validation: The FDA package describes segmentation of 3D CT data, registration to live fluoroscopic X-ray, integration with fluoroscopic imaging systems and external displays, DICOM import, and a main-unit, tablet, router, and board system.
Scope: Exact FDA submission. This is the interface boundary described in the exact FDA package; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.
Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.
Field checked 2026-09-04 · FDA 510(k) K240943: LungVision
Source context, not route validation: The FDA package describes an on-site main unit, tablet, router, board, and software integrated with fluoroscopic imaging systems and external displays; current hosting, service, availability, security, and site configuration remain unverified.
Scope: Exact FDA submission. This is the release-level boundary described in the exact FDA package; current hosting, contracts, security, availability, upgrade path, and site configuration remain separate evidence.
Confirm processing location, queue ownership, exclusions and exact AI build.
Field checked 2026-09-04 · FDA 510(k) K240943: LungVision
Source context, not route validation: Segmented CT anatomy, registered overlays, lesion marks, pathways, tomographic views, and 3D navigation views.
Scope: Exact FDA submission.
Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.
Field checked 2026-09-04 · FDA 510(k) K240943: LungVision
Unresolved route: Segmented CT anatomy, registered overlays, lesion marks, pathways, tomographic views, and 3D navigation views.
Scope: Exact FDA submission.
Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.
Field checked 2026-09-04 · FDA 510(k) K240943: LungVision
Unresolved route: Not established for the exact route.
Scope: Scope not established.
Name the local, platform and AI supplier support owners and escalation path.
No tests below have been performed or accepted.
Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.
This is the release-level boundary described in the exact FDA package; current hosting, contracts, security, availability, upgrade path, and site configuration remain separate evidence.
This is the interface boundary described in the exact FDA package; current local compatibility, routing, identity, archive, and downtime behavior still require acceptance testing.
This is buyer-facing monitoring guidance derived from the exact cleared or authorized scope; it is not a claim that the FDA package provides a live monitoring service.
Map installed model, build, options, population, anatomy, inputs, outputs, and enabled functions to K240943 before acceptance.
exact submission · checked 2026-09-04Later product-family features are not evidence that this cleared or authorized release includes them.
The FDA package describes an on-site main unit, tablet, router, board, and software integrated with fluoroscopic imaging systems and external displays; current hosting, service, availability, security, and site configuration remain unverified.
exact submission · checked 2026-09-04FDA-described deployment boundaries do not establish current hosting contracts, security controls, uptime, or local qualification.
The FDA package describes segmentation of 3D CT data, registration to live fluoroscopic X-ray, integration with fluoroscopic imaging systems and external displays, DICOM import, and a main-unit, tablet, router, and board system.
exact submission · checked 2026-09-04Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.
Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. Use is limited to the labeled pulmonary procedure, anatomy, supported imaging configuration, and professional review; navigation output does not replace clinical judgment.
exact submission · checked 2026-09-04Define stop-use, escalation, rollback, and revalidation triggers before production use.
Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.
product family · checked 2026-09-04No exact-product price was found in the reviewed public material; productivity or value claims require local evidence.
Monitor K240943 by exact hardware, software, model, and algorithm version; patient population; anatomy; protocol; operator; input quality; output edits or overrides; failed studies; repeat acquisition or rework; downstream impact; downtime; incidents; recalls; and updates. Track these product-specific limits: Use is limited to the labeled pulmonary procedure, anatomy, supported imaging configuration, and professional review; navigation output does not replace clinical judgment.
exact submission · checked 2026-09-04Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes. pulmonary procedure image-navigation software limits remain submission-specific.
Regulatory identity
The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.
Research record
This audit distinguishes completed source review from fields that have not yet been researched.
Seven PubMed records and two trial records were screened. Product-naming records concern LungVision generally, a first-generation system, or study-period configurations without linkage to the K240943 AI-Tomo configuration; all nine records are quarantined and none is promoted. The current discovery snapshot contains 7 PubMed and 2 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.
Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.
Source classes: fda ai list, fda decision summary, fda decision material, fda pma record, peer reviewed literature, clinical trial registry, reimbursement policy, fda device recall, pubmed, clinical trials, openfda device recall
Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.
No public list price for the exact cleared or authorized configuration was found. Obtain a written quote separating hardware or license basis, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.
Public materials reviewed for this exact release do not establish the complete security posture. Request data-flow, identity, audit, encryption, retention, remote-access, vulnerability-management, backup, and incident-response evidence.
6 sources - 3 history items
Scope: identity, purpose, clinicalUse, modality, anatomy, intendedUsers, careSetting, workflowRole, input, output, limitations, evidenceSummary
Scope: regulatoryIdentity, modalityContext
Scope: evidenceDiscovery
Scope: evidenceDiscovery, studyStatus
Scope: coverage, codingContext
Scope: recallDiscovery, nativeSubmissionMatching
Regulatory record
510(k)
Research record
human reviewed
Editorial review
Source-reviewed editorial overlay
Alternatives
Adas3D Medical S.L.
Authorized purpose: ADAS 3D supports visualization and analysis of MR and CT images of the heart for individual patients with cardiovascular disease, including patients with myocardial scar from ischemic or non-ischemic heart disease. Qualified professionals may use it for cardiac calculation, quantification, visualization, pre-planning, and electrophysiology procedures; produced data support clinical decision-making and must not be used as irrefutable medical advice or for radiotherapy planning, dose calculation, or treatment delivery.
Cercare Medical A/S
Authorized purpose: Cercare Neurosuite with Capillary Function and Oncology Virtual Expert processes CT or MR information to provide perfusion, tissue-blood-volume, diffusion, labeling, and quantification support for adult brain glioma workflows.
FUJIFILM Healthcare Americas Corporation
Synapse PACS 7.6.0 provides medical-image management and processing, including measurements, regional segmentation, clinical calculations, structured reports, comparison, fusion, and volume rendering to aid reading, interpretation, reporting, and treatment planning.
Neurophet., Inc.
Authorized purpose: Brain MRI/PET registration, segmentation and quantitative PET assessment
Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.
Open existing correction destinationPermission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.
No entry has been added to this scoped change history for this record. This is not proof that the record never changed.
Correction policy and limits · Public repository change history